Rationale: Azithromycin prevents acute exacerbations of chronic obstructive pulmonary
disease (AECOPDs); however, its value in the treatment of an AECOPD requiring …

Rationale: Daily azithromycin decreases acute exacerbations of chronic obstructive
pulmonary disease (AECOPD), but long-term side effects are unknown. Objectives: To …

Background The aim of this study was to determine whether long-term intermittent
azithromycin therapy reduces the frequency of exacerbation in severe chronic obstructive …

Rationale According to clinical trials, azithromycin taken daily for 1 year, decreased
exacerbations of chronic obstructive pulmonary disease (COPD). Objectives Effectiveness …

Long-term azithromycin therapy has been shown to reduce exacerbations of chronic
obstructive pulmonary disease (COPD), and is recommended by recent society guidelines …

Background Acute exacerbations adversely affect patients with chronic obstructive
pulmonary disease (COPD). Macrolide antibiotics benefit patients with a variety of …

Background In the BACE trial, a 3-month (3 m) intervention with azithromycin, initiated at the
onset of an infectious COPD exacerbation requiring hospitalization, decreased the rate of a …

Background Continuous treatment with azithromycin may lead to fewer acute exacerbations
of chronic obstructive pulmonary disease (AECOPD), but little is known of its impact on …

Background Macrolide resistance is an increasing problem; there is therefore debate about
when to implement maintenance treatment with macrolides in patients with chronic …

Patients with Chronic Obstructive Pulmonary Disease (COPD) and tracheostomy are at high
risk for exacerbations and hospitalizations. Macrolide treatment has shown to reduce …